Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVI002 + ezetimibe
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination medication that likely pairs ezetimibe with a statin or another cholesterol-lowering agent (AVI002). Ezetimibe works by preventing the absorption of cholesterol in the intestine, while the partner drug (possibly a statin) likely inhibits cholesterol production. This dual mechanism approach allows for greater LDL cholesterol reduction than either medication alone.
- Other names
- AVI002 + EzetimibeAvipero Ebola combination therapy
02
Targets
NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on AVI002 + ezetimibe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVI002 + ezetimibe.